In the past week, ENGN stock has gone up by 27.33%, with a monthly gain of 36.34% and a quarterly surge of 13.25%. The volatility ratio for the week is 13.65%, and the volatility levels for the last 30 days are 14.59% for enGene Holdings Inc The simple moving average for the past 20 days is 36.23% for ENGN’s stock, with a -7.21% simple moving average for the past 200 days.
Is It Worth Investing in enGene Holdings Inc (NASDAQ: ENGN) Right Now?
Moreover, the 36-month beta value for ENGN is -0.65. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ENGN is 16.22M and currently, short sellers hold a 3.07% of that float. On October 22, 2024, ENGN’s average trading volume was 191.01K shares.
ENGN) stock’s latest price update
The stock price of enGene Holdings Inc (NASDAQ: ENGN) has jumped by 8.98 compared to previous close of 9.02. Despite this, the company has seen a gain of 27.33% in its stock price over the last five trading days. businesswire.com reported 2024-10-21 that BOSTON & MONTREAL–(BUSINESS WIRE)–enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chie.
Analysts’ Opinion of ENGN
Many brokerage firms have already submitted their reports for ENGN stocks, with Oppenheimer repeating the rating for ENGN by listing it as a “Outperform.” The predicted price for ENGN in the upcoming period, according to Oppenheimer is $30 based on the research report published on August 28, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see ENGN reach a price target of $30. The rating they have provided for ENGN stocks is “Overweight” according to the report published on April 22nd, 2024.
Guggenheim gave a rating of “Buy” to ENGN, setting the target price at $34 in the report published on April 15th of the current year.
ENGN Trading at 45.36% from the 50-Day Moving Average
After a stumble in the market that brought ENGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.16% of loss for the given period.
Volatility was left at 14.59%, however, over the last 30 days, the volatility rate increased by 13.65%, as shares surge +53.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +48.71% upper at present.
During the last 5 trading sessions, ENGN rose by +27.33%, which changed the moving average for the period of 200-days by +38.06% in comparison to the 20-day moving average, which settled at $7.22. In addition, enGene Holdings Inc saw 6.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENGN starting from Forbion Growth Opportunities F, who purchase 341,332 shares at the price of $6.34 back on Sep 30 ’24. After this action, Forbion Growth Opportunities F now owns 2,400,791 shares of enGene Holdings Inc, valued at $2,163,362 using the latest closing price.
Forbion Growth Opportunities F, the 10% Owner of enGene Holdings Inc, purchase 41,639 shares at $5.97 during a trade that took place back on Sep 27 ’24, which means that Forbion Growth Opportunities F is holding 2,059,459 shares at $248,699 based on the most recent closing price.
Stock Fundamentals for ENGN
The total capital return value is set at -0.22. Equity return is now at value -103.02, with -94.04 for asset returns.
Based on enGene Holdings Inc (ENGN), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -1.43. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -17.27.
Currently, EBITDA for the company is -25.89 million with net debt to EBITDA at 2.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.52.
Conclusion
To wrap up, the performance of enGene Holdings Inc (ENGN) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
